
Overview
Read-Gene develops and commercializes genetic tests and offers services involving microelements and diet modifications. Its work also includes methods for detecting, preventing and treating malignant tumors, with DNA tests intended to support prevention and earlier treatment for people with genetic cancer predispositions. The company collaborates with medical professionals from the International Center for Hereditary Cancers at the Pomeranian Medical University in Szczecin.
- ul. Alabastrowa 8, 72-003 Dobra
- ul. Choroszczańska 24, 15-732 Białystok
- ul. Tadeusza Rejtana 1, 85-032 Bydgoszcz
- ul. Broniewskiego 9, 85-316 Bydgoszcz
- ul. Limanowska 22A, 33-395 Chełmiec
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $4,626 |
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 9 days for 2022). All were audited by a statutory auditor.
- 202501/07/2026
- 202414/07/2025
- 202319/07/2024
- 202224/07/2023
- 202113/07/2022
- 202003/08/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 4.74
- High
- PLN 4.80
- Low
- PLN 4.50
- Volume
- 760
- Avg. vol.
- 195
- Market cap
- PLN 56.59M
- P/E ratio
- 25.26
- EPS
- PLN 0.19
- Shares outstanding
- 11.79M
- 52-week
- PLN 4.50 – 4.88
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLRADGN00014
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD 901.67k | USD -80.23k | USD -79.96k |
| Q2 2026 | USD 1.13m | USD -116.96k | USD 113.45k |
| Q1 2026 | USD 1.05m | USD 203.94k | USD 199.08k |
| Q4 2025 | USD 1.29m | USD 193.12k | USD 108.74k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Industry
Offer
- Genetic tests
- Clinical trials
- Scientific research
- Micronutrient analyses
- Dietary modifications
Websites
The site is available in: Polish and English. The site targets these markets: United States.
- read-gene.comStrona główna – Read-Gene S.A.WordPress 7.1ElementorGoogle AnalyticsGoogle Tag ManagerYoast SEOApache
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. 6 marks have expired or were not registered. The first mark was filed in 2010.
| Mark | Protected until | |
|---|---|---|
| CYNK-GEN (word) | Oct 18, 2032 | |
| ONKOPAKIET READ-GENE (word) | – | |
| ONKOPIERWIASTKI READ-GENE (word) | – | |
| ONKOPAKIET (word) | – | |
| Fer-Nat (word) | – |
Authorized Representatives
Manner of representation
The following persons are authorized to submit declarations of will on behalf of the company: in the case of a one-person management board – the President of the Management Board or each of the commercial proxies independently, and in the case of a multi-member management board – the President of the Management Board independently, or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Innowacyjna Medycyna sp. z o.o. | 1,350.62 USD | 100% |
Bank accounts
Registered as a VAT taxpayer on 2010-09-30.
35 1240 3927 1111 0010 0756 5222
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $148.8K$148,818 |
Buildings and premises | $1.1M$1,105,301 |
Public aid
4 public aid cases recorded, with a total value of $40,999.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 9, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $24,952$24,952 | PGE Obrót S.A. | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $6,309$6,309 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,426$5,426 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Histamed Dc sp. z o.o. | $5,901,162.84 | histamed.pl | ||
| Akademicki Ośrodek Diagnostyki Patomorfologicznej I Genetyczno-Molekularnej sp. z o.o. | $5,089,922.17 | aodp.pl | ||
| Testdna sp. z o.o. | $5,035,995.35 | testdna.pl | ||
| Genos sp. z o.o. | $3,695,996.40 | genos.com.pl | ||
| Imedlab sp. z o.o. | $2,063,628.43 | imedlab.pl | ||
| Info-Pat sp. z o.o. sp. k. | $1,930,368.97 | info-pat.poznan.pl | ||
| Warsaw Genomics sp. z o.o. | $1,712,726.96 | warsawgenomics.pl | ||
| Laboratorium Analityczne sp. z o.o. | $1,626,233.76 | lab-zawadzkie.pl | ||
| Diagen Diagnostyka Genetyczna dla Rodziny sp. z o.o. | $1,200,587.96 | diagen.com.pl | ||
| Inngen Laboratorium Badań Genetycznych sp. z o.o. | $1,158,524.97 | inngen.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-09-03 | Switch to PKD 2007 (20 PKD 2004 codes → 10 PKD 2007 codes) | |
| 2009-06-19 | Share capital reduction (615,000.00 PLN → 589,500.50 PLN) | |
| 2009-01-16 | Share capital increase (500,000.00 PLN → 615,000.00 PLN) | |
| 2005-09-27 | Entered in the register |
FAQ
Last updated: 2026-08-20


